Skip to main content

Select Drug Profiles

Genetic Abnormality Pinpointed for Intensive Therapy in Wilms Tumor

Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers

Leukemia, Oncology

Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL

Leukemia, Oncology

Adherence to Ibrutinib Therapy Improves Outcomes in Patients with CLL

Immunotherapy, Oncology

Immunotherapies Steal the Show at ASCO 2015

Immunotherapy, Oncology

Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma

Arming Providers and Payers with Treatment- and Value-Based Management Tools for Battling Cancer

Matthew Mitchell, PharmD, MBA, FAMCP

Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis

Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma

Lisa A. Raedler, PhD, RPh

The Continuation of Care

David B. Nash, MD, MBA

Page 131 of 244
Results 1301 - 1310 of 2438